Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI325 Plus Sintilimab in Advanced Solid Tumors
NCT05246995Phase 1Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibi325 in solid tumor (advanced stage), sponsored by Shandong Cancer Hospital. Primary endpoints: Dose Limiting Toxicity at 42 days and Treatment Related Adverse Events at 90 days. Status: unknown.
02
Drugs
ibi325
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05246995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246995.